Research & Educational Use Only. All protocols for research purposes. Not medical advice. Not for human consumption.

Peptide Protocol Catalog

Research-grade dosage protocols sourced from peer-reviewed literature. Each full protocol includes dosing tables, reconstitution math, mechanism of action, and primary source citations.

36
Full protocols built
80+
Peptides cataloged
8
Research categories
0
Vendor promotions
🔬

Recovery & Tissue Repair

12 protocols
BPC-157 (5 mg Vial)
15-amino-acid gastric peptide studied for cytoprotection and tissue healing. Once-daily subcutaneous protocol with 11 peer-reviewed citations.
200–600 mcg/daySub-Q8–12 wks
Full Protocol →
BPC-157 (10 mg Vial)
Higher-volume vial format with proportionally adjusted reconstitution math. Same subcutaneous daily protocol framework.
200–600 mcg/daySub-Q
Full Protocol →
TB-500 / Thymosin Beta-4 (5 mg Vial)
43-amino-acid peptide regulating actin, cell migration, and angiogenesis. Loading + maintenance phase protocol with systemic distribution rationale.
2.5–5 mg/weekLoading PhaseSub-Q
Full Protocol →
KPV (10 mg Vial)
Tripeptide fragment of alpha-MSH. Studied for anti-inflammatory properties, gut mucosa research, and NF-κB inhibition. Oral and sub-Q routes covered.
500 mcg–2 mg/daySub-Q or oral
Full Protocol →
LL-37 (5 mg Vial)
Cathelicidin-derived antimicrobial peptide studied for immune modulation, wound healing, and antimicrobial defense.
100–500 mcg/daySub-Q
Thymosin Alpha-1 (1.6 mg Vial)
Immune-modulating peptide from thymosin fraction 5. Studied for immune dysregulation, chronic infections, and immune senescence.
1.6 mg 2×/weekSub-Q
📈

GH Secretagogues & Growth Hormone

18 protocols
CJC-1295 (No DAC) + Ipamorelin (10 mg Blend)
GHRH analog + selective GHS. Complementary pathways for synergistic pulsatile GH release. Once-daily protocol.
100–300 mcg each/dayDaily8–12 wks
Full Protocol →
Ipamorelin (10 mg Vial)
First selective GH secretagogue. GH release without cortisol/ACTH elevation. Low desensitization profile enables extended cycles.
100–300 mcg/dose1–3×/day8–16 wks
Full Protocol →
GHRP-2 / Pralmorelin (10 mg Vial)
Potent GHRP. Strong GH stimulation via dual pituitary + hypothalamic sites. Mild cortisol/ACTH elevation at higher doses.
100–300 mcg/dose1–3×/day
Full Protocol →
GHRP-6 (10 mg Vial)
Classic GHRP with the strongest appetite stimulation of any secretagogue. Potent GH release; cortisol elevation at high doses.
100–300 mcg/dose2–3×/day
Full Protocol →
Sermorelin (10 mg Vial)
GHRH(1–29) analog. Preserves IGF-1 negative feedback regulation. First GHRH analog approved by FDA (pediatric GHD). Before-sleep protocol.
200–500 mcg/dayBefore sleep12–24 wks
Full Protocol →
CJC-1295 DAC (2 mg Vial)
Long-acting GHRH analog with Drug Affinity Complex. ~6–8 day half-life via albumin binding. Once-weekly dosing schedule.
1–2 mg/weekOnce weekly
CJC-1295 NO DAC (5 mg Vial)
Short-acting GHRH analog (~30 min half-life). Produces natural GH pulses. Typically combined with GHRPs for synergistic release.
100–300 mcg/dose1–3×/day
HGH 191AA (10 IU Vial)
Recombinant human growth hormone. 191-amino acid somatotropin. Requires IU dosing; bypasses the GH axis entirely.
1–4 IU/daySub-Q16–24 wks
IGF-1 LR3 (1 mg Vial)
Long-acting IGF-1 analog. Downstream GH mediator with extended receptor binding. Direct anabolic and recovery effects.
20–100 mcg/daySub-Q
⚖️

Metabolic & Weight Management

14 protocols
Retatrutide (20 mg Vial)
Triple agonist (GLP-1/GIP/glucagon). Phase 2: up to 24% weight loss at 48 weeks. Comprehensive weekly titration protocol.
2–12 mg/weekOnce weekly24–48 wks
Full Protocol →
Semaglutide (5 mg Vial)
GLP-1 receptor agonist. Active compound in Ozempic/Wegovy. Full Wegovy titration ladder. STEP trial data included.
0.25–2.4 mg/weekOnce weekly16–68 wks
Full Protocol →
Tirzepatide (10 mg Vial)
Dual GIP/GLP-1 agonist. Active in Mounjaro/Zepbound. SURMOUNT data: 20.9% weight loss at 72 weeks on 15 mg.
2.5–15 mg/weekOnce weekly12–72 wks
Full Protocol →
Cagrilintide (5 mg Vial)
Long-acting amylin analog. Under investigation in combination with semaglutide (CagriSema). Satiety and appetite modulation.
0.3–2.4 mg/weekOnce weekly
AOD-9604 (5 mg Vial)
Modified C-terminal HGH fragment. Studied for fat metabolism without the anabolic or diabetogenic effects of full GH.
250–500 mcg/daySub-Q
5-Amino-1MQ (50 mg Vial)
NNMT inhibitor studied for adipocyte reduction in metabolic syndrome models. Oral administration research compound.
50–100 mg/dayOral
🧬

Longevity & Bioregulators

10 protocols
Epitalon / Epithalon (10 mg Vial)
Synthetic tetrapeptide (Ala-Glu-Asp-Gly). Studied for telomerase activation, pineal regulation, and aging biomarkers. 10–20 day cycle protocol.
5–10 mg/day10-day cycles2–3×/year
Full Protocol →
FOXO4-DRI (10 mg Vial)
FOXO4-p53 interaction disruptor. Studied as a senolytic agent — selectively inducing apoptosis in senescent cells. Intermittent cycle protocol.
1–5 mg/injection3-day cyclesMonthly
Full Protocol →
Cartalax (20 mg Vial)
Tripeptide bioregulator from cartilage. Studied for musculoskeletal aging and connective tissue gene expression regulation.
0.1–0.5 mg/daySub-Q
Cortagen (20 mg Vial)
Tetrapeptide bioregulator from aorta tissue. Studied for cardiovascular aging biomarkers and gene expression modulation.
0.1–0.5 mg/daySub-Q
Chonluten (20 mg Vial)
Tripeptide bioregulator from bronchial mucosa. Studied for respiratory epithelial aging and pulmonary biomarkers.
0.1–0.5 mg/daySub-Q
Livagen (20 mg Vial)
Tetrapeptide bioregulator from liver chromatin. Studied for chromatin decondensation and hepatic gene expression.
0.1–0.5 mg/daySub-Q
✨

Skin & Cosmetic Peptides

8 protocols
GHK-Cu (50 mg Vial)
Copper tripeptide. Naturally found in human plasma (declines with age). Studied for skin remodeling, collagen synthesis, and gene expression modulation of 4,000+ genes.
1–2 mg/injection3–5×/week8–12 wks
Full Protocol →
GHK-Cu (100 mg Vial)
High-volume vial format for extended protocols. Concentration: 3.0 mL BAC water → 33.3 mg/mL. Same mechanism and applications as 50 mg.
1–2 mg/day5 days on/2 off
Melanotan II (10 mg Vial)
Melanocortin receptor agonist. Studied for skin pigmentation, photoprotection, and sexual function. Non-selective MC receptor activity.
0.25–1 mg/daySub-Q
⚡

Hormonal & Sexual Health

9 protocols
HCG (5000 IU Vial)
Human chorionic gonadotropin. LH-mimetic. FDA-approved for cryptorchidism and hypogonadism. Testosterone support and fertility research.
250–1500 IU/dose2–3×/week
Full Protocol →
PT-141 / Bremelanotide (10 mg Vial)
Melanocortin agonist (MC3R/MC4R). FDA-approved as Vyleesi for HSDD. CNS sexual arousal mechanism. PRN (as-needed) protocol.
1.0–2.0 mg/dosePRNMax 1×/24 hrs
Full Protocol →
Gonadorelin (2 mg Vial)
GnRH decapeptide. Stimulates pulsatile LH and FSH release from pituitary. HPG axis research.
100 mcg/pulsePulsatile dosing
Kisspeptin-10 (10 mg Vial)
GPR54 receptor agonist. Upstream GnRH pulse inducer. Studied for LH pulsatility and reproductive hormone research.
1–2 nmol/kgSub-Q
HMG (75 IU Vial)
Human menopausal gonadotropin. FSH + LH combination studied for ovarian stimulation and fertility research applications.
75–150 IU/daySub-Q or IM
🧠

Cognitive & Neuroprotective

7 protocols
Cerebrolysin (60 mg Vial)
Porcine brain-derived neuropeptide mixture. Studied for neuroprotection, neuroplasticity, and recovery from neural injury. IV or IM protocols.
5–30 mL/dayIV or IM10–21 day cycles
Semax (30 mg Vial)
Synthetic heptapeptide ACTH analog. Studied for cognitive enhancement, neuroprotection, and BDNF upregulation. Intranasal protocol.
300–600 mcg/dayIntranasal
Selank (5 mg Vial)
Synthetic tuftsin analog with anxiolytic and cognitive effects. Studied for anxiety, stress modulation, and immune function.
250–3000 mcg/dayIntranasal or sub-Q
DSIP (10 mg Vial)
Delta Sleep-Inducing Peptide. Studied for sleep architecture modulation, stress response, and neuroendocrine function.
250–500 mcg/daySub-Q
🔗

Peptide Blends

15 protocols
BPC-157 + TB-500 (20 mg Blend)
High-dose recovery blend: 10 mg BPC-157 + 10 mg TB-500. Standard and loading-phase protocols. Complementary tissue-repair mechanisms.
500–1000 mcg total/day4–8 wks
Full Protocol →
CJC-1295 (No DAC) + Ipamorelin (10 mg)
GHRH analog + selective GHS. Synergistic pulsatile GH release via complementary receptor activation. Once-daily sub-Q.
100–300 mcg each/day8–12 wks
Full Protocol →
Semaglutide + Cagrilintide (CagriSema)
GLP-1 agonist + amylin analog combination. Under Phase 3 investigation. Dual satiety mechanism for weight management research.
Variable titrationOnce weekly
BPC-157 + TB-500 (10 mg Blend)
Lighter 10 mg version: 5 mg BPC-157 + 5 mg TB-500. Lower doses or shorter cycles. Same synergistic repair mechanism.
250–500 mcg total/day4–6 wks
GHRP-2 + CJC-1295 Blend (10 mg)
Potent GHRP + GHRH combination for amplified GH pulse. Classic synergistic secretagogue pairing.
100–300 mcg each/dose2–3×/day
Tesamorelin + Ipamorelin (10 mg Blend)
GHRH analog with strongest visceral fat evidence (HIV lipodystrophy trials) + selective GHRP. Synergistic GH release.
2 mg + 300 mcg/doseDaily